ERBB2 and breast carcinoma: Regarding comparators, the most common study setups contrasted TNBC vs. healthy controls and TNBC vs. other breast cancer subtypes (e.g., luminal, HER2-positive); fewer studies included benign breast lesions or mixed comparator groups.